Overweight

50
Pipeline Programs
14
Companies
50
Clinical Trials
5 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
28
0
5
0
14
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
24100%
+ 35 programs with unclassified modality

On Market (3)

Approved therapies currently available

Novo Nordisk
OZEMPICApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2017
Novo Nordisk
RYBELSUSApproved
semaglutide
Novo Nordisk
oral2020
Novo Nordisk
WEGOVYApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]oral2025

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
36 programs
14
3
14
1
CagrilintidePhase 3Peptide1 trial
CagrilintidePhase 3Peptide1 trial
CagrilintidePhase 3Peptide1 trial
CagrisemaPhase 31 trial
SemaglutidePhase 3Peptide1 trial
+31 more programs
Active Trials
NCT06240208Recruiting40Est. Mar 2026
NCT07141914Completed285,327Est. Dec 2025
NCT06874751Completed45,456Est. Mar 2025
+33 more trials
Rhythm Pharmaceuticals
2 programs
1
1
SetmelanotidePhase 2Peptide1 trial
RM-493Phase 11 trial
Active Trials
NCT02431442Completed57Est. Jan 2014
NCT01749137Completed74Est. Sep 2013
Abbott
AbbottABBOTT PARK, IL
1 program
1
Amino Acid Drink MixturePhase 21 trial
Active Trials
NCT00974831Completed24Est. Oct 2009
Amgen
AmgenTHOUSAND OAKS, CA
3 programs
3
AMG 133Phase 11 trial
Maridebart CafraglutidePhase 1Peptide1 trial
Maridebart CafraglutidePhase 1Peptide1 trial
Active Trials
NCT07310563Completed59Est. May 2025
NCT07226778Active Not Recruiting348Est. May 2026
NCT07229157Active Not Recruiting81Est. Aug 2026
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
3 programs
3
BI 456906Phase 11 trial
SurvodutidePhase 1Peptide1 trial
survodutidePhase 1Peptide1 trial
Active Trials
NCT06200467Completed110Est. Oct 2025
NCT06564441Completed34Est. Jan 2026
NCT06492135Completed30Est. Apr 2025
Pfizer
PfizerNEW YORK, NY
3 programs
3
Formulation APhase 11 trial
PF-07976016Phase 13 trials
PF-08653944Phase 11 trial
Active Trials
NCT05677867Completed20Est. Mar 2023
NCT07015918Completed8Est. Aug 2025
NCT06910839Terminated21Est. May 2025
+2 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
2
LY3502970Phase 11 trial
TirzepatidePhase 1Peptide1 trial
Active Trials
NCT06023095Completed24Est. Jul 2024
NCT04407234Completed36Est. Jan 2021
Rivus Pharmaceuticals
Rivus PharmaceuticalsVA - Charlottesville
1 program
1
HU6Phase 11 trial
Active Trials
NCT07170189CompletedEst. Dec 2025
Design Therapeutics
1 program
1
Switch active lifestyles brought to you by MediaWisePhase 11 trial
Active Trials
NCT00685555CompletedEst. Dec 2006
Pierre Fabre
Pierre FabreFrance - Aignan
2 programs
A form ArginineN/A1 trial
One form of arginineN/A1 trial
Active Trials
NCT02352740Completed
NCT02354794CompletedEst. Sep 2014
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
2 programs
Challenge! Small Group InterventionN/A1 trial
Machine Learning AlgorithmN/A1 trial
Active Trials
NCT03103269Completed789Est. Jan 2014
NCT02960386Completed184Est. Jul 2020
Francis Medical
Francis MedicalMN - Maple Grove
1 program
SisterTalk HartfordN/A1 trial
Active Trials
NCT01282749CompletedEst. Aug 2006
Precision BioSciences
1 program
Study product AN/A1 trial
Active Trials
NCT05710055Completed200Est. Apr 2023
Aura Biosciences
Aura BiosciencesMA - Boston
1 program
Training programN/A1 trial
Active Trials
NCT03940924CompletedEst. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Novo NordiskCagrisema
Novo NordiskCagrilintide
Novo NordiskCagrilintide
Novo NordiskSemaglutide
Novo NordiskSemaglutide
Novo NordiskCagrilintide
Novo NordiskSemaglutide
Novo NordiskSemaglutide
Novo NordiskSemaglutide
Novo NordiskSemaglutide
Novo NordiskSemaglutide
Novo NordiskSemaglutide
Novo NordiskSemaglutide
Novo NordiskSemaglutide
Novo NordiskUBT251

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 312,623 patients across 50 trials

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

Start: Jun 2026Est. completion: Jan 20281,400 patients
Phase 3Not Yet Recruiting

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Start: Jan 2026Est. completion: Sep 2033460 patients
Phase 3Recruiting

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Start: Nov 2025Est. completion: Jun 2027330 patients
Phase 3Active Not Recruiting

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

Start: Sep 2023Est. completion: May 2025242 patients
Phase 3Completed

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

Start: May 2023Est. completion: Jan 2025200 patients
Phase 3Completed

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Start: Feb 2023Est. completion: Feb 20251,200 patients
Phase 3Completed

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

Start: Oct 2022Est. completion: May 2024307 patients
Phase 3Completed

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

Start: Dec 2020Est. completion: Aug 2022375 patients
Phase 3Completed

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

Start: Oct 2019Est. completion: Mar 2022201 patients
Phase 3Completed

Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

Start: Sep 2019Est. completion: May 2021338 patients
Phase 3Completed

STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity

Start: Jan 2019Est. completion: Nov 2020401 patients
Phase 3Completed

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Start: Oct 2018Est. completion: Jun 202317,604 patients
Phase 3Completed

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Start: Oct 2018Est. completion: Mar 2021304 patients
Phase 3Completed

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

Start: Aug 2018Est. completion: Apr 2020611 patients
Phase 3Completed

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

Start: Feb 2026Est. completion: Feb 2027333 patients
Phase 2Recruiting

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

Start: Oct 2025Est. completion: Dec 2026220 patients
Phase 2Recruiting

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Start: Mar 2019Est. completion: Mar 2021706 patients
Phase 2Completed

Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants

Start: Jan 2013Est. completion: Sep 201374 patients
Phase 2Completed
NCT00974831AbbottAmino Acid Drink Mixture

Glucose Tolerance in Healthy Overweight Adults

Start: Jul 2009Est. completion: Oct 200924 patients
Phase 2Completed

A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

Start: Feb 2026Est. completion: Jan 202796 patients
Phase 1Recruiting
NCT07411560Novo NordiskGlucose-dependent Insulinotropic Polypeptide

A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese

Start: Feb 2026Est. completion: Jan 2027100 patients
Phase 1Not Yet Recruiting

A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity.

Start: Feb 2026Est. completion: Sep 202654 patients
Phase 1Recruiting
NCT07229157AmgenMaridebart Cafraglutide

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

Start: Oct 2025Est. completion: Aug 202681 patients
Phase 1Active Not Recruiting

Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6

Start: Oct 2025Est. completion: Dec 2025
Phase 1Completed
NCT07226778AmgenMaridebart Cafraglutide

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

Start: Oct 2025Est. completion: May 2026348 patients
Phase 1Active Not Recruiting

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.

Start: Aug 2025Est. completion: Dec 202536 patients
Phase 1Completed

A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity

Start: Aug 2025Est. completion: Oct 2025100 patients
Phase 1Completed

A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men

Start: Jun 2025Est. completion: Aug 20258 patients
Phase 1Completed

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

Start: Mar 2025Est. completion: May 202521 patients
Phase 1Terminated

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing

Start: Feb 2025Est. completion: May 202529 patients
Phase 1Completed

A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity

Start: Dec 2024Est. completion: Jul 2025100 patients
Phase 1Completed

A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity

Start: Dec 2024Est. completion: May 202559 patients
Phase 1Completed

A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults

Start: Nov 2024Est. completion: Jan 202512 patients
Phase 1Completed

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Start: Oct 2024Est. completion: Jan 202634 patients
Phase 1Completed

A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body

Start: Aug 2024Est. completion: Apr 202530 patients
Phase 1Completed

A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity

Start: Mar 2024Est. completion: Oct 2025110 patients
Phase 1Completed
NCT06267092Novo NordiskNo treatment given

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

Start: Feb 2024Est. completion: Dec 2025164 patients
Phase 1Completed

A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

Start: Sep 2023Est. completion: Jul 202424 patients
Phase 1Completed
NCT05677867PfizerFormulation A

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

Start: Jan 2023Est. completion: Mar 202320 patients
Phase 1Completed

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

Start: Sep 2020Est. completion: Jan 202136 patients
Phase 1Completed

A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens

Start: Feb 2020Est. completion: Oct 2020111 patients
Phase 1Completed

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

Start: Jan 2020Est. completion: Jan 202133 patients
Phase 1Completed

A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Start: Dec 2019Est. completion: Sep 202068 patients
Phase 1Completed

Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant

Start: Sep 2019Est. completion: Mar 202031 patients
Phase 1Completed

A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Start: Jul 2019Est. completion: Oct 201929 patients
Phase 1Terminated

A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity

Start: Jul 2019Est. completion: Jun 2022103 patients
Phase 1Completed

A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity

Start: Feb 2019Est. completion: Nov 201972 patients
Phase 1Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers

Start: Jan 2012Est. completion: Jan 201457 patients
Phase 1Completed
NCT00685555Design TherapeuticsSwitch active lifestyles brought to you by MediaWise

Healthy Futures Project: A Community Based Obesity Prevention Program

Start: Oct 2005Est. completion: Dec 2006
Phase 1Completed
NCT07141914Novo NordiskNo treatment given

A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World

Start: Aug 2025Est. completion: Dec 2025285,327 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

14 late-stage (Phase 3) programs — potential near-term approvals
5 actively recruiting trials targeting 312,623 patients
14 companies competing in this space